---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-047174"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:31:44.174044+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics appoints Stelios Papadopoulos to Board of Directors

## Summary
- Board expanded from five to six directors; Papadopoulos appointed Class I director, term through 2027 annual meeting.
- Papadopoulos co-founded Exelixis, served as Chairman of Biogen (2014-2023), and has extensive biotech investment banking background.
- Appointed to Audit Committee and Compensation Committee, effective March 1, 2025.
- Non-employee director compensation updated: $45,000 base retainer, initial 90,000 stock options grant, annual 45,000 options.
- Entered standard indemnification agreement covering expenses for actions arising from director service.

## SEC filing metadata
- accession: 0001193125-25-047174
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000119312525047174/0001193125-25-047174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000119312525047174/d844381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-047174
- JSON: https://secwatch.observer/filing/0001193125-25-047174.json
- Plain text: https://secwatch.observer/filing/0001193125-25-047174.txt

## Key facts
- Executive change
  Stelios Papadopoulos was appointed as Class I director at Ovid Therapeutics Inc..
  - Action: appointed
  - Role: Class I director
  source text: On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525047174/0001193125-25-047174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.